Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer

Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer

Gemcitabine is used to treat gallbaldder cancer but patient responses are variable. Here, the authors use a genome-wide CRISPR screen and identify the translational elongator protein ELP5 as a protein that is important for mediating gemcitabine-induced apoptosis.

Bibliographic Details
Main Authors: Sunwang Xu, Ming Zhan, Cen Jiang, Min He, Linhua Yang, Hui Shen, Shuai Huang, Xince Huang, Ruirong Lin, Yongheng Shi, Qiang Liu, Wei Chen, Man Mohan, Jian Wang
Format: Article
Language:English
Published: Nature Publishing Group 2019-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-13420-x

Internet

https://doi.org/10.1038/s41467-019-13420-x

Similar Items